We’re thrilled to announce that Digistain® is now available to selected UK private patients, with reimbursement available though Bupa, WPA Health Insurance & Healix.
Tim Woodman, Medical Director at Bupa’s Policy and Cancer Services, said:
“I’m really excited to be working with Digistain.”
Digistain has been nominated for the EIT Awards 2026 in the Venture Award category. The Venture Award recognises organisations combining strong commercial potential with meaningful
In September 2026 Sasha Becejac, Digistain’s CCO, was invited to speak at On Targeted Molecular Oncology 2026 in Ankara, Türkiye, sharing the latest developments around
In September 2026 Sarah Bond, our COO for the MENA region, took part in The Future Health Dialogue roundtable hosted at Hub71 in Abu Dhabi,
Supported by:
To stay updated about Digistain’s developments, enter your details opposite. We promise only to send you important news.